The report “Superdisintegrants Market by Product (Modified Starch, Modified Cellulose, Crospovidone, Ion Exchange Resin), Formulation (Tablet, Capsules), Therapeutic Area (Gastrointestinal, Cardiovascular, Neurology, Oncology, Hematology) – Global Forecast”, is expected to reach USD 536.5 million, at a CAGR of 7.9%.
Recent Developments:
– In October 2017, Roquette opened a new Pharmaceutical R&D and Customer Technical Service (CTS) in Biopolis (Singapore) for the development of new products and new applications for existing products as well as pre-clinical research. This new facility operates as Roquette’s Asia Pacific headquarters and focuses on food, nutrition, and pharma products.
– In March 2017, BASF Group opened the Innovation Campus Asia Pacific in India, marking the company’s largest R&D investment in South Asia. The company invested USD 61.6 million (EUR 50 million) in this center to increase its global and regional research activities.
– In October 2016, Ashland opened a new pharmaceutical excipient facility in Nanjing, China, to produce excipients for the Asian market. The company supplies highly functional excipient technologies to manufacturers of oral pharmaceuticals and provide tailor-made formulation solutions through this facility
Request Research Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=198068672
Superdisintegrants Market
The tablets segment is expected to hold the largest share in 2018
Based on formulation, is segmented into tablets and capsules. In 2018, the tablets segment is estimated to account for the largest share of the superdisintegrants market. Benefits such as stability, low manufacturing cost (as compared to other dosage forms), easy product identification, and compactness are driving the production of tablet formulations. The increasing focus on fast and orally disintegrating tablets is also contributing to the large share of this segment.
Geographical View in-detailed:
Europe is expected to account for the largest share of the superdisintegrants market in 2018, followed by North America and Asia Pacific. The large share of this region can be attributed to the presence of a number of pharmaceutical giants with large production capacities leading to high consumption of excipients. The growing emphasis on superior pharmaceutical products and generics is also expected to aid the market growth in the region. Moreover, a number of major global players are based in Germany.
Global Key Leaders:
The prominent players in the global superdisintegrants market are Ashland Inc. (US), BASF SE (Germany), DowDuPont (US), JRS Pharma (Germany), DFE Pharma (Germany), Roquette Freres (France), Asahi Kasei Corporation (Japan), Merck KGaA (Germany), Corel Pharma Chem (India), and Avantor Performance Materials, LLC (US).
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198068672
BASF was the leading player in the superdisintegrants market and accounted for the largest share in 2017. The company offers a well-balanced portfolio for the market. Its stronghold in the global pharmaceutical excipients market is primarily attributed to its innovative product portfolio and strong relationships with its customers. Additionally, having a large number of production sites gives it a competitive advantage over other players in the excipients market. The company also provides customized products to make customers’ production processes more efficient. To remain competitive in the market, the company focuses on expanding its presence across the globe. It opened Innovation Campus Asia Pacific in India with an initial investment of USD 2.76 million. By 2020, the company plans to conduct around 25% of its global R&D in Asia Pacific.
Ashland was the second-largest market player in the superdisintegrants market in 2017. The company offers crospovidone for the largest market. Ashland’s prominent position in the market is attributed to its research and development activities, robust manufacturing capabilities, and an extensive distribution network across the world, which enables it to serve customers in over 100 countries. The company’s growth strategy for the pharmaceutical excipients business mainly concentrates on expanding its production capacity and meet the rising customer demand. The company majorly focuses on expansions to grow and maintain its position in the market.
